Mepolizumab Yields Lower Rate of Moderate/Severe Exacerbations in COPD

Medically reviewed by Carmen Pope, BPharm. Last updated on May 12, 2025.

By Elana Gotkine HealthDay Reporter

MONDAY, May 12, 2025 -- For patients with chronic obstructive pulmonary disease (COPD) with a history of exacerbations and a blood eosinophil count of at least 300 cells/µL, mepolizumab leads to a lower annualized rate of moderate or severe exacerbations, according to a study published in the May 1 issue of the New England Journal of Medicine.

Frank C. Sciurba, M.D., from the University of Pittsburgh, and colleagues conducted a randomized, placebo-controlled trial involving patients with COPD, a history of exacerbations, and a blood eosinophil count of at least 300 cells/µL who were receiving triple inhaled therapy. Patients were randomly assigned to receive mepolizumab 100 mg or placebo subcutaneously every four weeks for 52 to 104 weeks (403 and 401 individuals, respectively).

The researchers found that the annualized rate of moderate or severe exacerbations was significantly lower with mepolizumab than placebo (0.80 versus 1.01 events per year; rate ratio, 0.79). Compared with placebo, the time to first moderate or severe exacerbation was longer with mepolizumab (419 versus 321 days; hazard ratio, 0.77). There were no significant between-group differences seen in measures of health-related quality of life and symptoms. A similar incidence of adverse events was seen in the mepolizumab and placebo groups.

"These findings indicate that mepolizumab treatment provides additional benefit to patients receiving guideline-based maintenance therapy alone," the authors write.

Several authors disclosed ties to biopharmaceutical companies, including GSK, which manufactures mepolizumab and funded the study.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords